A number of trials have been undertaken to test the efficacy of chlorphentermine (l-(p-chlorophenyl)-2-methyl 2-aminopropane hydrochloride; Lucofen) as an anorectic agent, and it has been shown to be superior to placebo (Lucey and Hadden, 1962; Levin et al., 1963) . Recently a sustained-action chlorphentermine (chlorphentermine S.A.) has become available and has been used by Seaton et al. (1964) in a group of patients with "refractory obesity" as defined by Duncan et al. (1960) . Their results showed a small but significant loss of weight after six weeks by patients on chlorphentermine S.A. compared with those on a dummy preparation, but thereafter the loss of weight was not significant.
For many obese patients the difficulties in losing weight by adherence to low-calorie diets are immense, and the availability of a drug which can act as an appetite suppressant would theoretically seem of advantage In such cases. In practice the anorectic agents, most of which are derived from amphetamine, have not only proved disappointing in the management of obesity but have also produced serious side-effects, including habituation and addiction (Kiloh and Brandon, 1962) . Modell (1960) has suggested that the anorexigenic action of the amphetamines is closely related to their cortical excitatory action, a fact which probably accounts for their addictive qualities. Chlorphentermine differs chemically from amphetamine (see Formulae) and appears to be metabolized differently, probably owing to the para-chloro substitution; certainly neither in experimental animals (Holm et al., 1960) nor in therapeutic dosage in clinical practice (Levin et al., 1963) has chlorphentermine been reported to produce cortical stimulation.
We herewith report a clinical trial of chlorphentermine S.A. in a group of obese patients attending an endocrine clinic. At the same time the opportunity was taken to make a number of observations on these patients, in particular their urinary steroid levels, during the course of the trial.
Materials and Methods
Forty patients (Table I) After 12 weeks the patients were discharged for three months ; they were all told to attend their general practitioners, to whom letters were written asking them to prescribe chlorphentermine S.A. one tablet daily in the morning for three months. The patients were then told to reattend the clinic. Those who had lost more than 1 stone (6.4 kg.) in weight over six months were subsequently asked to report back after a further three months to assess their progress.
Before dietary and drug measures were instituted most patients had a 24-hour urine estimated for 17-ketosteroids (17-KS) and total 17-hydroxycorticosteroids (17-OHCS) (Few, 1961) , and this was repeated after three months on the trial. Any striae or hirsutism in these patients were noted. Side-effects.-The incidence of side-effects in those taking chlorphentermine S.A. was 13 (65%) compared with four (20 %) for the placebo. The most common complaints of the chlorphentermine patients were nausea with or without headaches and dizziness. In addition to nausea one patient had vomiting and one had dryness in the back of the throat. Other complaints noted were diarrhoea in one patient and " a lump in the back of the throat " in one patient. The complaints of those on placebo were " nervous rash," nausea, dizziness, and constipation. No patient withdrew from the trial as a result of side-effects from the tablets. The gastro-intestinal complaints of those on chlorphentermine S.A. occurred usually in the first month and gradually wore off, ceasing to be troublesome. In a few instances the patients stopped the tablets for two or three days before resuming them again.
Patients Seen After Nine Months.-Ten patients who had lost more than 1 stone (6.4 kg.) in weight by six months were recalled three months later. Eight patients attended, and of these three had continued to lose weight (3, 3, and 8 lb.
(1,360, 1,360, and 3,630 g.) respectively), three had remained at the same weight, and two had put on weight (3 and 11 lb. (1,360 and 4,990 g.) respectively). Only four patients still continued to take chlorphentermine, and three of these had lost weight and one had remained steady.
Discussion
It is not easy to design an ideal clinical trial for an appetite suppressant. We have tested chlorphentermine S.A. not only in a double-blind trial with all the aura of frequent hospital attendances and mystery bottles with coded numbers, but also in the more mundane manner of asking the general practitioner to write out a prescription for some " pill." In the context of a hospital clinic in which repeated doses of encouragement and explanation of dietary principles are given at frequent intervals, chlorphentermine S.A. is shown to be more efficient than a placebo in catalysing loss of weight over a period of three months. However, away from the influence of the four-weekly attendance at a special clinic, so-called adherence to dietary measures plus chlorphentermine S.A. produced no significant loss of weight. Seaton et al. (1964) found in their patients that chlorphentermine S.A. was effective as an anorectic only in the first six weeks of being prescribed, after which it ceased to be effective. Under clinical trial conditions we have found it to be effective for three months, but an increased tolerance to the drug could be a factor in the lack of further response in the test group of patients. However, in the placebo group of patients chlorphentermine S.A. did not produce any significant loss of weight in the second three-monthly period, the mean weight loss during this period being 3.2 lb. (1,450 g.) compared with 4.6 lb. (2,085 g.) while on the dummy preparation.
The incidence of a family history of diabetes or obesity was high, but this was found to bear no relation to subsequent loss of weight ; nor was any effect determined by the initial level of 17-KS and total 17-OHCS.
After dieting for three months both the 17-KS and total 17-OHCS levels in the urine fell, the latter falling significantly. The fall in urinary steroid excretion correlated with loss of weight, but not statistically (P>0.05). Cohen (1958) found a decrease in urinary steroid excretion in obese children placed on low-calorie diets and suggested that over-nutrition may produce functional hyperpituitarism or hyperadrenocorticism or both. Simkin (1961) There was a strong family history of diabetes and obesity, but this bore no relation to subsequent loss of weight.
After three months' dieting the mean total 17-OHCS and 17-KS fell, the former significantly. The fall in urinary steroid excretion correlated with the loss of weight, but not statistically so.
The value of chlorphentermine S.A. and the indications for its use are discussed.
In 1954 Paulley described an abnormal appearance of the small-intestinal mucosa in a few patients with idiopathic steatorrhoea. With the introduction of peroral biopsy by Shiner (1956) the number of observations was greatly increased and the abnormal appearance confirmed in both idiopathic steatorrhoea and coeliac disease (Shiner and Doniach, 1960; Shiner, 1960) . The abnormality is easy to recognize both by the dissecting microscope (Holmes et al., 1961a ) and on histology. It consists of loss of the normal villous pattern with a flat or convoluted appearance, and, on section, deep crypts opening on to a disorganized surface epithelium. This histological appearance has been regarded as specific for a disease entity-coeliac disease and idiopathic steatorrhoea.
We have been impressed by the number of cases in which a flat mucosa has been associated with other diseases, suggesting that the mucosal change may be a non-specific response in some patients. This report concerns a group of patients in whom a flat mucosa was found and details the associated disease present at the time of the biopsy.
Definitions
This paper frequently refers to three concepts-a mucosal abnormality, a clinical picture, and a disease entity. The clinical picture is described in a separate communication (1961b) later showed that each corresponded to a dissecting-microscope appearance, a flattened surface in subtotal and a convoluted appearance in partial villous atrophy. The difficulty is that some workers appear to include rather minor abnormalities under partial villous atrophy, and also that other conditions may produce a convoluted appearance (Creamer, 1964a) . In our opinion a distinction is usually easy if attention is paid not only to the structure but also to the presence of chronic inflammatory cells in the stroma and degenerative changes in the surface epithelium with lymphocytic infiltration. Most of the cases described here had a flattened appearance on examination with the dissecting microscope, and all showed the changes of inflammation and epithelial degeneration. This we call a flat mucosa.
Disease entity.-Under the labels of idiopathic steatorrhoea, adult coeliac disease, and non-tropical sprue, a disease is recognized which may be linked with coeliac disease of childhood
